Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R21)

archived

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), encourages Exploratory/Developmental Research Grant Award (R21) applications from institutions/organizations that propose to evaluate the pharmacokinetics of anti-tuberculosis (anti-TB) drugs and pharmacokinetic drug interactions between anti-TB drugs and anti-HIV medications in children with HIV/TB co-infection. Research in this area lags far behind that in adults due to the many challenges surrounding the diagnosis and management of TB disease in children. Research related to the treatment of TB in the context of pediatric HIV/TB co-infection is urgently needed. This FOA will support investigator-initiated grants to define appropriate dosing of anti-TB agents in HIV-infected children and will generate knowledge leading to the optimization of management of TB/HIV co-infection in children, including the management of central nervous system (CNS) involvement with TB through the evaluation of CNS penetration of anti-TB agents in the context of antiretroviral therapy. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental Research Grant (R21) award mechanism and is issued in parallel with an FOA of identical scientific scope, RFA-HD-09-015 that encourages applications under the R01 grant mechanism. Funds Available and Anticipated Number of Awards. The NICHD intends to commit $250,000 (total costs), and NIMH intends to commit $150,000 (total costs) in FY 2010 to support one to two meritorious applications. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

High